Castrate Resistant Prostate Cancer Clinical Trial
Official title:
A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors.
EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor which has demonstrated antitumor activity in in vitro and in vivo models of human cancer. This Phase I open-label, multi-center, dose-escalation study will assess the safety and determine the maximum tolerated dose of EP31670 administered orally in patients with castration-resistant prostate cancer, NUT midline carcinoma and other targeted advanced solid tumors. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Withdrawn |
NCT05191017 -
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04296578 -
Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone
|
Phase 1 | |
| Recruiting |
NCT05655715 -
Checkpoint Inhibitors and SBRT for mCRPC
|
Phase 2 | |
| Recruiting |
NCT06395519 -
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT01144897 -
PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy
|
Phase 1 | |
| Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT01352208 -
Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04969315 -
TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT01313559 -
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT04319783 -
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
|
Phase 2 | |
| Recruiting |
NCT05627752 -
Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage
|
Phase 2/Phase 3 | |
| Terminated |
NCT04737109 -
Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01907009 -
A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05570994 -
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT05159518 -
A Study of PRT2527 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT04541225 -
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT05156372 -
Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients
|
N/A | |
| Recruiting |
NCT05766371 -
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT04335682 -
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
|
Phase 2 |